Main Menu

First patient dosed in a Phase 2 study with LiPlaCis in prostate cancer

Image result for prostate cancer patient

Press release

Hoersholm, Denmark and Cambridge, MA, US, March 11, 2019 – Oncology Venture A/S (“OV” or “the Company”) today announced that the first patient has been dosed in a Phase 2 study with LiPlaCis® in prostate cancer. Oncology Venture has clearance from the Danish health authorities to treat up to 15 prostate cancer patients with LiPlaCis®. Just as in the ongoing Phase 2 study with LiPlaCis® in breast cancer, Oncology Venture’s drug response prediction technology, DRP®, will be used to identify the prostate cancer patients most likely to respond to the LiPlaCis®-treatment.

LiPlaCis® is an intelligent, target controlled liposome formulation of one of the world’s most widely used chemotherapies, cisplatin. The specific LiPlaCis® formulation allows delivery of LiPlaCis® directly at tumor site. Oncology Ventures diagnostic tool DRP® selects the patients whom are expected to benefit from the treatment. LiPlaCis® has shown very promising results in an ongoing phase 2 study in patients with metastatic breast cancer.

The study will examine if patients with prostate cancer respond to LiPlaCis® in the same way as patients with breast cancer, and the first patient has now been dosed at the University Hospital in Herlev Denmark. The prostate cancer patients will be selected with the diagnostic tool DRP®. The results are measured by response rate (number of patients with reduced tumor volume), time to progression (time from treatment start until the disease starts to worsen or spread) and time to progression compared to the individual patient’s previous therapy results. Only patients with a LiPlaCis® DRP® above the bottom 33% are included in the trial.

It is known that platin products are active in prostate cancer, but previous clinical studies have not been able to show sufficient effect to obtain marketing approval. We believe this is mainly due to treating a too broad patient population and will examine if the DRP can identify the individuals who benefit from the LiPlaCis treatment as we can do in breast cancer,” comments Peter Buhl Jensen, M.D., CEO of Oncology Venture.

For further information, please contact:

For investor inquiries
Ulla Hald Buhl, IR & Communications
E-mail: uhb@oncologyventure.com
Telephone +45 21 70 10 49
For media inquiries
Thomas Pedersen, Carrotize PR & Communications
E-mail: tsp@carrotize.com
Telephone +45 60 62 93 90





Leave a Reply

Your email address will not be published. Required fields are marked *